Get started
Author

Dustin Chapin

Phase II trial of elotuzumab with pomalidomide and dexamethasone for daratumumab-refractory multiple myeloma
2024 · Ricardo D. Parrondo, Betsy R. LaPlant, et al. · Blood Cancer Journal · 7
PDF
Ibrutinib, lenalidomide and dexamethasone in patients with relapsed and/or refractory multiple myeloma: Phase I trial results
2022 · Sikander Ailawadhi, Ricardo D. Parrondo, et al. · Hematological Oncology · 6
A phase II study of ibrutinib in combination with ixazomib in patients with Waldenström macroglobulinaemia
2024 · Ricardo D. Parrondo, Navnita Dutta, et al. · British Journal of Haematology · 4
PDF
Phase II Study of Ibrutinib in Combination with Ixazomib in Patients with Waldenström Macroglobulinemia (WM)
2022 · Sikander Ailawadhi, Ricardo D Parrondo, et al. · Blood · 4
Phase II Trial of Elotuzumab with Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma (RRMM) in the Post-Daratumumab Progression Setting
2022 · Sikander Ailawadhi, Ricardo D Parrondo, et al. · Blood · 4
A pilot single-arm, pragmatic trial in progress of in-home versus in-clinic subcutaneous nivolumab administration through Cancer Care (connected access and remote expertise) Beyond Walls (CCBW) program.
2025 · Dina Elantably, Jeremy Clifton Jones, et al. · Journal of Clinical Oncology · 2
Peri-Transplant and Maintenance Daratumumab for Minimal Residual Disease (MRD) Eradication in Transplant-Eligible Multiple Myeloma (MM) Patients
2022 · Sikander Ailawadhi, Ricardo D Parrondo, et al. · Blood · 2
Time-Limited Maintenance with Ibrutinib after First-Line Therapy and the Incremental Impact on Minimal Residual Disease (MRD) for Patients with Chronic Lymphocytic Leukemia (CLL)
2022 · Sikander Ailawadhi, Ricardo D Parrondo, et al. · Blood · 1
Phase I Trial of Ibrutinib, Lenalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM)
2019 · Sikander Ailawadhi, Aneel Paulus, et al. · Blood · 1
A phase II study of daratumumab and ibrutinib for relapsed/refractory chronic lymphocytic leukemia
2026 · Ricardo D. Parrondo, Sikander Ailawadhi, et al. · Blood Cancer Journal
PDF
Works count: 10
Citation count: 31
H-index: 4
I10-index:
Year
Topic
Type